微门户首页  新闻  讨论区  活动  博客  求职招聘  行业报告  圈内成员  供应   
已读[167] 发布: 2013/05/27 15:29:42
Daily Mail Then, amazingly, I met a good and loving man, Mark, now 47 - the estate agent I had hired to sell my house - who was prepared to take on me and my bereft daughter, who had lost her sister and never known her father. We married in 2004 at St ... Two-and ... and more »
已读[126] 发布: 2013/05/24 18:31:33
公司目前抗肿瘤药物规模较小,产品线尚未完善,仅有一个治疗晚期乳腺癌的肿瘤药物阿那曲唑片,本次获注册批件的注射用左亚叶酸钙是重庆华邦制药有限公司肿瘤领域的第二...
已读[121] 发布: 2013/05/24 18:28:27
familydoctor.com.cn 芳香化酶抑制剂如来曲唑和 阿那曲唑 对性功能的影响并不清楚,我们需要更多的试验来回答这些问题。 放射治疗会引起局部改变,影响乳房敏感性,导致纤维化,皮肤增厚,挛缩或皮肤纹理和颜色改变,有时甚至引起乳腺疼痛,任 ... and more »
已读[116] 发布: 2013/05/23 17:46:55
Oncology Nurse Advisor The ATAC trial included nearly 10,000 women who were treated with surgery followed by five years of anastrozole , tamoxifen, or a combination of both. The transATAC study included 1,125 of these women from the monotherapy arms (either anastrozole or ...
已读[443] 发布: 2013/05/23 14:10:30
日前在上海举办的“全程守护,得领未来”2013第九届阿斯利康乳腺癌高峰论坛上,来自全国的肿瘤专家对于乳腺癌内分泌治疗给予了特别关注。他们认为,选择一种适合的治疗...
已读[165] 发布: 2013/05/20 15:53:38
pharmabiz.com ... for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer (advanced HR+/HER2 negative breast cancer) in combination with exemestane after failure of treatment with letrozole or anastrozole .
已读[334] 发布: 2013/05/20 15:49:21
新民晚报 据邵志敏教授介绍,乳腺癌内分泌治疗的基本药物有抗雌激素药物(如他莫西芬、氟维司群),芳香化酶抑制剂(如阿那曲唑)、促黄体生成素释放激素(LHRH)类似物(如 戈舍瑞林 )、雌雄激素和孕激素。 如果在内分泌辅助治疗后或治 ... and more »
已读[413] 发布: 2013/05/20 14:46:51
因为体内肿瘤存在,是否有效,两个月左右就能见分晓。 据邵志敏教授介绍,乳腺癌内分泌治疗的基本药物有抗雌激素药物(如他莫西芬、氟维司群),芳香化酶抑制剂(如阿...
已读[113] 发布: 2013/05/19 15:45:53
PipelineReview.com (press release) ... for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer (advanced HR+/HER2 negative breast cancer) in combination with exemestane after failure of treatment with letrozole or anastrozole . and more »
已读[115] 发布: 2013/05/18 15:45:36
PipelineReview.com (press release) ... for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer (advanced HR+/HER2 negative breast cancer) in combination with exemestane after failure of treatment with letrozole or anastrozole . and more »
« 上一页  |   查看结果91-100共122   |  下一页 »

新闻标签:

没有标签


最新报告


求职招聘